Clay Sie­gall’s $614M wa­ger on tu­ca­tinib pays off with solid­ly pos­i­tive piv­otal da­ta and a date with the FDA

Back at the be­gin­ning of 2018, Clay Sie­gall snagged a can­cer drug called tu­ca­tinib with a $614 mil­lion cash deal to buy

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.